ArticlePloS one2021

Development and evaluation of inhalable composite niclosamide-lysozyme particles: A broad-spectrum, patient-adaptable treatment for coronavirus infections and sequalae.

Ashlee D Brunaugh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.